Evidence map›Paper›PMID 34790250›Full record

ArticleComputational and mathematical methods in medicine2021

Correlation between Imaging Features and Pathological Stages of Primary Lung Tumors Based on Nanocontrast Agents.

Jin Li, Qian Xu, Cunhua Mao, Yuliang Liu

Abstract read
In one paragraph

Article in Computational and mathematical methods in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jin LiDepartment of Radiology, Jinan Third People's Hospital, Jinan, Shandong, China.
Qian XuDepartment of Image, Jinan Municipal Hospital of Traditional Chinese Medicine, Jinan, Shandong, China.
Cunhua MaoDepartment of Radiology, The Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
Yuliang LiuDepartment of Image, Jinan Municipal Hospital of Traditional Chinese Medicine, Jinan, Shandong, China.ORCID https://orcid.org/0000-0002-1140-468X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As one of the conventional methods of lung cancer detection, computed tomography (CT) usually requires the use of contrast agents to enhance the imaging effect. Conventional iodine contrast agents have poor signal-to-noise ratio and are prone to adverse reactions. It is necessary to find more effective and safe contrast agents for CT scans. The gold nanoparticles with secondary electron effect and photoelectric absorption effect can prolong the display time of the patient's blood circulation after being injected into the patient's body, which makes the nanocontrast agent a research hotspot in the field of CT imaging. In this study, ultrasmall gold nanoclusters with a diameter of about 5 nm were used as the contrast agent in CT scans. It was found that CT scans based on nanocontrast agents can obtain high-quality lung cancer imaging images, and the patient has no obvious adverse reactions. When observing the CT image, it was found that the stage of lung cancer patients can be clearly distinguished through the CT scan image. When analyzing the consistency of CT imaging and pathological classification, the Kappa value was 0.810, indicating that the two have a high degree of consistency. Therefore, this study believes that the imaging characteristics of primary lung tumors based on nanocontrast agents are highly correlated with their pathological types.

Indexed as

Contrast MediaMetal NanoparticlesComputational BiologyGoldHumansLung NeoplasmsNanotechnologyNeoplasm StagingParticle SizeTomography, X-Ray ComputedContrast MediaGold

Identifiers

PMID34790250
PMCPMC8592732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.